A randomized, placebo-controlled, double-blinded pilot study using carvedilol-CR as a p-glycoprotein inhibitor as adjunct therapy in the treatment of medically-refractory epilepsy.

Trial Profile

A randomized, placebo-controlled, double-blinded pilot study using carvedilol-CR as a p-glycoprotein inhibitor as adjunct therapy in the treatment of medically-refractory epilepsy.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs Carvedilol (Primary)
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Apr 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov
    • 25 Apr 2011 Planned end date changed from 1 Dec 2010 to 1 Apr 2011 as reported by ClinicalTrials.gov.
    • 25 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top